These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

72 related articles for article (PubMed ID: 6511457)

  • 21. Factors associated with the development of motor fluctuations and dyskinesias in Parkinson disease.
    Hauser RA; McDermott MP; Messing S
    Arch Neurol; 2006 Dec; 63(12):1756-60. PubMed ID: 17172616
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Usefulness of increasing the proportion of carbidopa to levodopa in the long-term treatment of Parkinson's disease].
    Bermejo Pareja F; Martínez-Martín P
    Med Clin (Barc); 1984 Feb; 82(7):305-10. PubMed ID: 6717135
    [No Abstract]   [Full Text] [Related]  

  • 23. Levodopa unresponsive symptoms in Parkinson disease.
    Sethi K
    Mov Disord; 2008; 23 Suppl 3():S521-33. PubMed ID: 18781679
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Advanced course of Parkinson disease. Little improved motion with continuous intestinal levodopa administration].
    Oberpichler-Schwenk H
    Med Monatsschr Pharm; 2005 Jul; 28(7):245-6. PubMed ID: 16038123
    [No Abstract]   [Full Text] [Related]  

  • 25. [Sialorrhea in patients with Parkinson. A six year prospective study].
    Serrano-Dueñas M
    Rev Neurol; 2003 Oct 1-15; 37(7):623-6. PubMed ID: 14582017
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and tolerability of levetiracetam in Parkinson disease patients with levodopa-induced dyskinesia.
    Lyons KE; Pahwa R
    Clin Neuropharmacol; 2006; 29(3):148-53. PubMed ID: 16772814
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Levodopa-associated dyskinesia risk among Parkinson disease patients in Olmsted County, Minnesota, 1976-1990.
    Van Gerpen JA; Kumar N; Bower JH; Weigand S; Ahlskog JE
    Arch Neurol; 2006 Feb; 63(2):205-9. PubMed ID: 16476808
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of caffeine on levodopa pharmacokinetics and pharmacodynamics in Parkinson disease.
    Deleu D; Jacob P; Chand P; Sarre S; Colwell A
    Neurology; 2006 Sep; 67(5):897-9. PubMed ID: 16966563
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A comparative study of bromocriptine and levodopa in Parkinson's disease.
    Duvoisin RC; Mendoza MM; Yahr MD
    Adv Biochem Psychopharmacol; 1980; 23():271-5. PubMed ID: 7395618
    [No Abstract]   [Full Text] [Related]  

  • 30. [Drug therapy in Parkinson's disease].
    van Hilten JJ; Roos RA
    Ned Tijdschr Geneeskd; 1999 Jan; 143(5):234-40. PubMed ID: 10086151
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Current controversies: levodopa in the treatment of Parkinson's disease.
    Sharma JC; Vassallo M; Ross IN
    Mov Disord; 2005 May; 20(5):642-3; author reply 643-4. PubMed ID: 15732129
    [No Abstract]   [Full Text] [Related]  

  • 32. Levodopa effect upon functional balance of Parkinson's disease patients.
    Nova IC; Perracini MR; Ferraz HB
    Parkinsonism Relat Disord; 2004 Oct; 10(7):411-5. PubMed ID: 15465397
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Acute effects of styrene inhalation on the neuroendocrinological system of rats and the different effects in male and female rats.
    Umemura T; Kurahashi N; Kondo T; Katakura Y; Sata F; Kawai T; Kishi R
    Arch Toxicol; 2005 Nov; 79(11):653-9. PubMed ID: 16021418
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Value of low-dose dopa therapy in Parkinson disease].
    Petit H; Rousseaux M; Mazingue A; Warot P
    LARC Med; 1983; 3(7):514-6. PubMed ID: 6645742
    [No Abstract]   [Full Text] [Related]  

  • 35. A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study.
    Parkinson Study Group
    Arch Neurol; 2005 Feb; 62(2):241-8. PubMed ID: 15710852
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pituitary function and the somatotrophic system in patients with idiopathic Parkinson's disease under chronic dopaminergic therapy.
    Schaefer S; Vogt T; Nowak T; Kann PH;
    J Neuroendocrinol; 2008 Jan; 20(1):104-9. PubMed ID: 18081558
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Progression and prognosis in Parkinson's disease in relation to concomitant cerebral or peripheral vasculopathy.
    Scigliano G; Musicco M; Soliveri P; Girotti F; Giovannini P; Fetoni V; Caraceni T
    Adv Neurol; 1996; 69():305-9. PubMed ID: 8615143
    [No Abstract]   [Full Text] [Related]  

  • 38. [Neuroendocrine regulation of immunogenesis in alcoholism].
    Aliev NA
    Probl Endokrinol (Mosk); 1988; 34(2):29-32. PubMed ID: 2839820
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cholinergic modulation of growth hormone, prolactin and thyroid stimulating hormone responses to thyrotropin-releasing hormone in normal aging.
    Giusti M; Giovale M; Sessarego P; Carraro A; Pompei A; Giordano G
    Recenti Prog Med; 1995 Sep; 86(9):341-4. PubMed ID: 7569294
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long-duration response to levodopa influences the pharmacodynamics of short-duration response in Parkinson's disease.
    Zappia M; Colao R; Montesanti R; Rizzo M; Aguglia U; Gambardella A; Oliveri RL; Quattrone A
    Ann Neurol; 1997 Aug; 42(2):245-8. PubMed ID: 9266736
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.